Related Experiment Video
Updated: May 13, 2026
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
High-throughput neural stem cell-based drug screening identifies S6K1 inhibition as a selective vulnerability in
Leilei Zhou1, Niek van Bree1, Lola Boutin1
1Department of Microbiology, Tumor, and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden.
Background:
Medulloblastoma (MB) is one of the most common malignant brain tumors in children. Current treatments have increased overall survival but can lead to devastating side effects and late complications in survivors, emphasizing the need for new, improved targeted therapies that specifically eliminate tumor cells while sparing the normally developing brain.
Methods:
Here, we used a sonic hedgehog (SHH)-MB model based on a patient-derived neuroepithelial stem cell system for an unbiased high-throughput screen with a library of 172 compounds with known targets. Compounds were evaluated in both healthy neural stem cells (NSCs) and tumor cells derived from the same patient. Based on the difference of cell viability and drug sensitivity score between normal cells and tumor cells, hit compounds were selected and further validated in vitro and in vivo.
Results:
We identified PF4708671 (S6K1 inhibitor) as a potential agent that selectively targets SHH-driven MB tumor cells while sparing NSCs and differentiated neurons. Subsequent validation studies confirmed that PF4708671 inhibited the growth of SHH-MB tumor cells both in vitro and in vivo, and that knockdown of S6K1 resulted in reduced tumor formation.
Conclusions:
Overall, our results suggest that inhibition of S6K1 specifically affects tumor growth, whereas it has less effect on non-tumor cells. Our data also show that the NES cell platform can be used to identify potentially effective new therapies and targets for SHH-MB.
Insights
A new study identified PF4708671, an S6K1 inhibitor, as a targeted therapy for sonic hedgehog medulloblastoma (SHH-MB). This compound selectively eliminates SHH-MB tumor cells while sparing healthy brain cells, offering a promising new treatment avenue.
Area of Science:
- Pediatric neuro-oncology
- Cancer drug discovery
- Molecular targeted therapy
Background:
- Medulloblastoma (MB) is a common pediatric brain tumor.
- Current treatments cause significant side effects and late complications.
- There is a critical need for targeted therapies that spare developing brain tissue.
Purpose of the Study:
- To identify novel therapeutic agents for sonic hedgehog medulloblastoma (SHH-MB).
- To evaluate drug candidates for selective toxicity against SHH-MB tumor cells versus normal neural stem cells (NSCs).
Main Methods:
- Utilized a patient-derived neuroepithelial stem cell (NES) system for SHH-MB modeling.
- Conducted a high-throughput screen of 172 compounds against tumor and normal cells.
- Validated promising compounds in vitro and in vivo.
Main Results:
- Identified PF4708671, an S6K1 inhibitor, as selectively targeting SHH-MB cells.
- PF4708671 demonstrated efficacy in inhibiting SHH-MB growth both in vitro and in vivo.
- Knockdown of S6K1 significantly reduced tumor formation, confirming its role.
Conclusions:
- S6K1 inhibition specifically targets SHH-MB tumor growth with minimal impact on non-tumor cells.
- The NES cell platform is effective for identifying new therapies and drug targets for SHH-MB.
- PF4708671 represents a promising therapeutic candidate for SHH-MB treatment.
